Boston Therapeutics, Inc.
BTHE · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -42.8% | -48.5% | 8.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | -243.2% | -65.4% | -111.6% | 100% |
| R&D Expenses | $0 | $2 | $0 | $0 |
| G&A Expenses | $1 | $1 | $2 | $1 |
| SG&A Expenses | $1 | $2 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $1 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $3 | $2 | $1 |
| Operating Income | -$1 | -$3 | -$2 | -$1 |
| % Margin | -8,418.3% | -21,392.8% | -6,409.9% | -4,311.4% |
| Other Income/Exp. Net | -$0 | $1 | -$2 | -$0 |
| Pre-Tax Income | -$1 | -$4 | -$4 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$4 | -$4 | -$2 |
| % Margin | -9,724.5% | -22,622.8% | -11,352.1% | -5,398.8% |
| EPS | -0.008 | -0.036 | -0.035 | -0.031 |
| % Growth | 77.2% | -2.6% | -14% | – |
| EPS Diluted | -0.008 | -0.036 | -0.035 | -0.031 |
| Weighted Avg Shares Out | 111 | 102 | 102 | 51 |
| Weighted Avg Shares Out Dil | 111 | 102 | 102 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$2 | -$3 | $0 |
| % Margin | -5,112.8% | -11,507.2% | -8,549.5% | 471.7% |